medwireNews : The US FDA has expanded the label for the tumor necrosis factor (TNF) inhibitor golimumab to include two pediatric indications.

Golimumab slows radiographic progression in patients with psoriatic arthritis, regardless of the extent of disease activity achieved or the composite index used to measure it, GO-VIBRANT study data show.

Findings from the real-world GO-EASY study suggest that treatment with the tumor necrosis factor inhibitor golimumab is associated with a significant reduction in the risk for acute anterior uveitis among patients with ankylosing spondylitis.

Findings from the real-world GO-EASY study suggest that treatment with the tumor necrosis factor inhibitor golimumab is associated with a significant reduction in the risk for acute anterior uveitis among patients with ankylosing spondylitis.

medwireNews : The US FDA has expanded the indications for the tumor necrosis factor inhibitor golimumab to include psoriatic arthritis (PsA) and ankylosing spondylitis (AS).

Researchers have observed a “remarkably high rate” of sustained clinical remission among patients with early peripheral spondyloarthritis treated with golimumab.

Intravenous golimumab is a promising treatment option for patients with psoriatic arthritis, results of the placebo-controlled GO-VIBRANT trial suggest.

Treatment with the anti-tumor necrosis factor α antibody golimumab could improve disease activity in children with polyarticular-course juvenile idiopathic arthritis, researchers report.

A total of 290,608 adverse events were reported from patients with RA, aged 18–75 years, between January 2011 and April 2022, of which 50,694 were for a JAK inhibitor (tofacitinib, baricitinib, upadacitinib, filgotinib) and 239,914 were for a TNF inhibitor (etanercept, adalimumab, infliximab, certolizumab pegol, golimumab).

Etanercept was the most commonly initiated treatment (27%), followed by adalimumab (14%), infliximab (13%), rituximab (12%), tocilizumab (10%), certolizumab pegol (9%), abatacept (9%), golimumab (6%), and baricitinib and tofacitinib (<1% each).

Monthly golimumab was increased to every 2 months, abatacept and tocilizumab from every 4 weeks to every 8 weeks, and rituximab was reduced from two 1000 mg intravenous infusions every 6 months to one infusion.

Weinblatt pointed out that five TNF inhibitors are currently approved for RA – etanercept, infliximab, adalimumab, golimumab, and certolizumab pegol – with a raft of evidence from many studies supporting their use.

When the TNF inhibitors were analyzed separately, only etanercept and infliximab were associated with a significantly lower CVD risk relative to conventional DMARDs, which the researchers attribute to “the relatively lower number of patients” taking adalimumab, golimumab, or certolizumab pegol.

And in the safety analysis, certolizumab pegol was associated with a significantly greater risk for infection compared with abatacept, anakinra, etanercept, golimumab, and tocilizumab (RR=1.35–1.53).

Of these, 72% stopped treatment with their first TNF inhibitor (etanercept, adalimumab, infliximab, certolizumab pegol, or golimumab) during a maximum 13.5 years of follow-up.

A systematic review and network meta-analysis finds few significant differences in the benefits and harms associated with different biologics when given in combination with methotrexate for the treatment of rheumatoid arthritis.